2020. In vitro Synergy of Ceftazidime-Avibactam Plus Rifampin Against Pseudomonas aeruginosa
Session: Poster Abstract Session: Antimicrobial Resistant Infections: Treatment
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • IDSA_Poster.pdf (595.1 kB)
  • Background:

    Pseudomonas aeruginosa is a major cause of nosocomial infections. An emerging concern is the increased prevalence of multidrug-resistance limiting treatment options. Ceftazidime-avibactam (CZA), FDA-approved February 2015, is a novel cephalosporin/non-β-lactam β-lactamase inhibitor coupling that demonstrates antipseudomonal activity. Despite its recent release, resistance to this agent has been reported. Rifampin (RI) has shown in vitro and in vivo synergistic activity when combined with β-lactams and polymyxins against P. aeruginosa. The aim of this study was to investigate any antimicrobial synergistic activity of the combination of CZA and RI against CZA-R P. aeruginosa isolates.

    Methods:

    P. aeruginosa isolates were prospectively collected from 193 consecutive patients during the last five months of 2015. Recovery sources were respiratory (45%), urinary (24%), wound (16%), bloodstream (9%), and other (6%) infections. Initial antimicrobial susceptibilities were determined by MicroScan. CZA and RI MICs (µg/mL) were determined by Etest. FDA MIC (µg/mL) interpretive guidelines for CZA are ≤8 susceptible, ≥16 resistant. There are no CLSI or FDA interpretive guidelines for testing RI against P. aeruginosa. Rep-PCR analysis was used to determine that CZA-R isolates were genetically unique. MICs and synergy testing (MIC: MIC method) of CZA-R isolates were performed in triplicate. The summation fractional inhibitory concentration (∑FIC) was calculated: synergy, <0.5; additivity, >0.5-1.

    Results:

    9/193 (5%) P. aeruginosa isolates were resistant to CZA, including 6/27 (22%) with multidrug-resistance (resistant to >1 agent in >3 antimicrobial categories). In vitro synergy by Etest was detected in 5/9 (56%) isolates (∑FICs 0.2-0.4) and additivity, 4 (∑FIC 0.6-1).

    Conclusion:

    Even though ceftazidime-avibactam demonstrated excellent activity in the P. aeruginosa isolates tested, resistance has already occurred. However, in vitro synergy or additivity was demonstrated against these CZA-R isolates with CZA plus rifampin. This combination should be further tested with additional isolates. In vitro synergy may not predict in vivo response.

    Diane Sibley, B.S.1, Shelby Simar, B.S.1, Deborah Ashcraft, B.S.1 and George Pankey, MD, FIDSA2, (1)Institute of Translational Research; Laboratory of Infectious Disease Research, Ochsner Clinic Foundation, New Orleans, LA, (2)Infectious Diseases, Ochsner Clinic Foundation, New Orleans, LA

    Disclosures:

    D. Sibley, None

    S. Simar, None

    D. Ashcraft, None

    G. Pankey, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.